MARKET

SIOX

SIOX

Sio Gene Therapies Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.450
-0.010
-0.41%
Opening 13:39 05/11 EDT
OPEN
2.340
PREV CLOSE
2.460
HIGH
2.480
LOW
2.330
VOLUME
379.83K
TURNOVER
--
52 WEEK HIGH
5.74
52 WEEK LOW
1.860
MARKET CAP
143.94M
P/E (TTM)
-2.1291
1D
5D
1M
3M
1Y
5Y
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs. Here is a look back at the week in SPACs for deals, rumors and headline news all covered on Benzinga’s “SPACs Attack.”
Benzinga · 2d ago
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 3d ago
Sio Gene Therapies (SIOX) Receives a Buy from Chardan Capital
Chardan Capital analyst Keay Nakae reiterated a Buy rating on Sio Gene Therapies (SIOX) today. The company's shares closed last Tuesday at $2.58.
SmarterAnalyst · 05/04 14:16
Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company
A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning.
Benzinga · 05/03 15:24
UPDATE 2-Biotech firm Roivant Sciences to go public via $7.3 bln SPAC deal
reuters.com · 05/03 11:24
Benzinga's Top Ratings Upgrades, Downgrades For April 30, 2021
 
Benzinga · 04/30 14:04
Bristol-Myers cut to neutral at Morgan Stanly noting an ‘uninspired’ pipeline, Community Health upgraded after Q1 results; and more in today’s analyst action
Bristol-Myers and Community Health Systems have seen their rating changed after reporting two contrasting performances with their Q1 financials. Today’s analyst action also includes a few initiations.Bristol-Myers downgraded at Morgan Stanley;
Seekingalpha · 04/30 13:25
Sio Gene Therapies (SIOX) Receives a Buy from H.C. Wainwright
In a report released today, Joseph Pantginis from H.C. Wainwright initiated coverage with a Buy rating on Sio Gene Therapies (SIOX) and a price target of
SmarterAnalyst · 04/30 10:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SIOX. Analyze the recent business situations of Sio Gene Therapies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SIOX stock price target is 8.70 with a high estimate of 12.50 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 14.29M
% Owned: 24.33%
Shares Outstanding: 58.75M
TypeInstitutionsShares
Increased
16
3.21M
New
27
3.44M
Decreased
8
303.12K
Sold Out
15
3.47M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
-0.15%
Key Executives
Chairman/Director
Frank Torti
Chief Executive Officer/Director
Pavan Cheruvu
Chief Financial Officer/Chief Accounting Officer/General Counsel
David Nassif
Other
Gavin Corcoran
Other
Parag Meswani
Lead Director/Independent Director
Atul Pande
Director
Eric Venker
Director
Kristiina Vuori
Independent Director
Berndt Modig
Independent Director
Senthil Sundaram
No Data
  • All
  • Financials
  • Insiders
More
About SIOX
Sio Gene Therapies Inc., together with its wholly owned subsidiaries, is a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. The Company is developing a pipeline of product candidates for the treatment of these debilitating diseases, including Parkinson's disease, GM1 gangliosidosis and GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease). The Company’s subsidiaries include Axovant Holdings Ltd, Axovant Sciences Inc, Axovant Sciences GmbH, Axovant Sciences Amercia, Inc., Axovant Treasury Holdings, Inc., Axovant Treasury, Inc and Axovant Sciences Europe Ltd. The Company’s clinical-stage programs include AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2 program.

Webull offers kinds of Sio Gene Therapies Inc stock information, including NASDAQ:SIOX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SIOX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SIOX stock methods without spending real money on the virtual paper trading platform.